Curated News
By: NewsRamp Editorial Staff
May 19, 2025
DarioHealth Receives Buy Rating with $3 Price Target, Analyst Forecasts Over 350% Upside Potential
TLDR
- DarioHealth Corp. poised for 350% upside potential with comprehensive chronic care platform.
- DarioHealth shifted to B2B2C model, driving 398% recurring revenue growth in Q4 2024.
- DarioHealth's integrated solution targets common chronic conditions, aiming to improve patient outcomes.
- DarioHealth's expansion into GLP-1 weight management market shows promising clinical outcomes and growth potential.
Impact - Why it Matters
This news matters as it highlights DarioHealth's transformation and growth trajectory, positioning it as a key player in the digital health space. Investors may find the company's unique business model and revenue projections compelling. Consumers could benefit from Dario's integrated solution for managing chronic conditions effectively.
Summary
Litchfield Hills Research has initiated coverage of DarioHealth Corp. (NASDAQ: DRIO) with a Buy rating and a $3 price target, forecasting significant upside potential. DarioHealth has transitioned to a B2B2C model, driving strong revenue growth and strategic acquisitions. The company's comprehensive platform addresses multiple chronic conditions.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, DarioHealth Receives Buy Rating with $3 Price Target, Analyst Forecasts Over 350% Upside Potential
